NCT01205932 - Dose-confirmatory Bridging Study in Total Hip Replacement | Biotech Hunter

Enrollment

402

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

August 31, 2011

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (BAY59-7939)

Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)

DRUG

Rivaroxaban (BAY59-7939)

Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)

DRUG

Rivaroxaban (BAY59-7939)

Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)

DRUG

Enoxaparin

daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)

Trial Locations (41)

455-8530

Nagoya

271-8511

Matsudo

275-8580

Narashino

790-8524

Matsuyama

813-0017

Fukuoka

814-8525

Fukuoka

963-8501

Kōriyama

078-8237

Asahikawa

040-8611

Hakodate

060-8648

Sapporo

675-8545

Kakogawa

657-0068

Kobe

663-8501

Nishinomiya

305-0854

Tsukuba

890-0014

Kagoshima

247-0061

Kamakura

236-0004

Yokohama

862-8505

Kumamoto

602-8026

Kyoto

395-8505

Iida

857-0135

Sasebo

857-8575

Sasebo

710-8522

Kurashiki

901-0243

Tomigusuku

573-1191

Hirakata

573-8511

Hirakata

594-0071

Izumi

598-8577

Izumisano

596-8501

Kishiwada

596-8522

Kishiwada

530-0012

Osaka

553-0003

Osaka

558-8558

Osaka

599-8271

Sakai

589-8511

Sayama

564-0082

Suita

569-1192

Takatsuki

849-8501

Saga

177-8521

Nerima-ku

158-0095

Setagaya City

930-8550

Toyama